Please provide your email address to receive an email when new articles are posted on . Tremfya is an interleukin-23 inhibitor being evaluated for the treatment of psoriatic arthritis.

As a chronic condition, rheumatoid arthritis (RA) can't be cured, so treatment focuses on managing the disease and controlling its progression. Although current treatments help control RA symptoms in ...

NEW YORK (Reuters Health) - Some studies have suggested that moderate drinkers have a lower risk of developing rheumatoid arthritis, and now new findings link the habit to a slower progression of the ...

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints. Specifically, the immune system is attacking the body’s own tissues thinking they are pathogenic or deleterious. It ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...

Women are disproportionately affected by almost every major form of arthritis, and the gap isn’t small. The pattern shows up ...

—A recent study designed to estimate the frequency of arthralgia at risk for progression to psoriatic arthritis (ARP-PsA) and to analyze prognostic variables found that, of those who met ARP-PsA, 29% ...

Your knees crack when you stand up, but you dismiss it as normal aging or leftover effects from old sports injuries. However, researchers have discovered that certain knee cracking patterns can ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

As of 2020, about 17.6 million people globally were living with rheumatoid arthritis, an autoimmune disease causing painful inflammation and swelling in joints. Scientists are still not sure as to the ...

Inflammation is the body’s defence system, a way of responding to injury or infection. One key molecule involved in the ...